伊布替尼耐药慢性淋巴细胞白血病中克隆内增殖亚群的早期重现
该研究通过流式细胞术纵向追踪慢性淋巴细胞白血病(CLL)患者中CXCR4dim/CD5bright增殖分数(PF)在伊布替尼治疗下的长期变化。PF最初被伊布替尼抑制,但在疾病早期进展时重现,且不依赖淋巴细胞计数或血清β2微球蛋白。57%的进展病例检出BTK/PLCG2体细胞突变,这些突变在PF中显著富集且等位基因频率为非PF部分的3倍。PF增加也见于无BTK/PLCG2突变的进展病例,提示PF可作为伊布替尼治疗下CLL进展的标志物。
要点
- 伊布替尼治疗下约30%的患者最终出现疾病进展。
- CXCR4dim/CD5bright增殖分数在早期疾病进展时重现,与淋巴细胞计数或血清β2微球蛋白无关。
- BTK/PLCG2突变在57%的进展病例中检出,并在增殖分数中富集,等位基因频率为非增殖分数的3倍。
核心结论
- 通过流式细胞术纵向监测CXCR4dim/CD5bright增殖分数可能提供一种简单工具,帮助拦截伊布替尼治疗下的CLL进展。
研究设计与样本
- 研究采用流式细胞术对伊布替尼治疗的慢性淋巴细胞白血病患者进行纵向追踪,分析CXCR4dim/CD5bright增殖分数的长期变化及其与治疗结局和伊布替尼耐药出现的关系。
主要发现
- 约30%的伊布替尼治疗患者最终出现疾病进展。
- 增殖分数最初被伊布替尼抑制,但在早期疾病进展时重现,且与淋巴细胞计数或血清β2微球蛋白无关。
- 57%的进展病例检出BTK/PLCG2体细胞突变,这些突变在增殖分数中显著富集,等位基因频率为非增殖分数部分的3倍。
- 无BTK/PLCG2突变的进展病例也出现增殖分数增加。
- 有或无BTK/PLCG2突变的进展病例中,增殖分数的转录组谱不同,提示B细胞受体信号再激活或通过MYC和/或Toll样受体9的旁路信号出现。
临床怎么用
- 作者认为,通过流式细胞术纵向监测CXCR4dim/CD5bright增殖分数可能提供一种简单工具,帮助拦截伊布替尼治疗下的CLL进展。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib represents an effective strategy for treatment of chronic lymphocytic leukemia (CLL), nevertheless about 30% of patients eventually undergo disease progression. Here we investigated by flow cytometry the long-term modulation of the CLL CXCR4dim/CD5bright proliferative fraction (PF), its correlation with therapeutic outcome and emergence of ibrutinib resistance. By longitudinal tracking, the PF, initially suppressed by ibrutinib, reappeared upon early disease progression, without association with lymphocyte count or serum beta-2-microglobulin. Somatic mutations of BTK/PLCG2, detected in 57% of progressing cases, were significantly enriched in PF with a 3-fold greater allele frequency than the non-PF fraction, suggesting a BTK/PLCG2-mutated reservoir resident within the proliferative compartments. PF increase was also present in BTK/PLCG2-unmutated cases at progression, indicating that PF evaluation could represent a marker of CLL progression under ibrutinib. Furthermore, we evidence different transcriptomic profiles of PF at progression in cases with or without BTK/PLCG2 mutations, suggestive of a reactivation of B-cell receptor signaling or the emergence of bypass signaling through MYC and/or Toll-Like-Receptor-9. Clinically, longitudinal monitoring of the CXCR4dim/CD5bright PF by flow cytometry may provide a simple tool helping to intercept CLL progression under ibrutinib therapy.
引用
- Pozzo F, Forestieri G, Vit F, et al. Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia. Leukemia. 2024. PMID: 38914716. doi:10.1038/s41375-024-02301-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。